EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy

Randomisierte, doppelblinde, placebokontrollierte Studie zu Olanzapin versus Placebo plus Ondansetron und Dexamethason zur antiemetischen Prophylaxe bei Patient:innen unter oxaliplatin-, irinotecan- oder carboplatinbasierter Chemotherapie

Warangkana Harikul, Akarin Nimmannit, Apirom Laocharoenkeat, Pochamana Phisalprapa, Chayanis Kositamongkol, Phurita Thongkijpreecha, Suthinee Ithimakin

Supportive Care in Cancer · 2026-03 · 34 (3)

DOI: 10.1007/s00520-026-10490-8 ↗

Auf einen Blick

Bei 139 auswertbaren Patient:innen verbesserte Olanzapin 5 mg zusätzlich zu Ondansetron und Dexamethason die antiemetische Kontrolle gegenüber Placebo. Der primäre Endpunkt wurde knapp verfehlt.

Fragestellung

Ist niedrig dosiertes Olanzapin zusätzlich zu Ondansetron und Dexamethason bei oxaliplatin-, carboplatin- oder irinotecanbasierter Chemotherapie wirksam gegen CINV?

Methode

Doppelblinde, randomisierte kontrollierte Studie; 1:1-Randomisierung auf Olanzapin 5 mg oder Placebo an Tag 1–4 plus Ondansetron und Dexamethason; Stratifizierung nach Chemotherapie und Hochrisikofaktoren.

Ergebnisse

139 auswertbare Patient:innen: 69 Olanzapin, 70 Placebo. Total protection 71,0 % vs. 55,7 % (p=0,06); total control 62,3 % vs. 38,6 % (p=0,005); Delir?

Schlussfolgerung der Autor:innen

Olanzapin 5 mg zusammen mit Ondansetron und Dexamethason war mit einer moderaten Verbesserung von total protection sowie signifikanten Verbesserungen von no-nausea und total control verbunden.

Kernaussagen

  • Total protection: 71,0 % vs. 55,7 %; p=0,06
  • Total control: 62,3 % vs. 38,6 %; p=0,005
  • 95,6 % der Olanzapin-Gruppe wollte das Schema fortsetzen

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 24.02.2026. Verfasst von Warangkana Harikul und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Antiemetics, Nausea, Vomiting, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siriraj Research Development Fund (Managed by Routine to Research: R2R), Mahidol University, Mahidol University.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

A two-drug regimen of palonosetron and dexamethasone is standard for moderately emetogenic chemotherapy (MEC), including oxaliplatin and irinotecan. Current guidelines recommend adding an NK1 receptor antagonist for carboplatin-based or MEC in patients with high-risk features. Given the comparable efficacy of olanzapine, this study evaluated the effectiveness of low-dose olanzapine (OLN, 5 mg) combined with ondansetron and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV).

Methods

In this double-blind, randomized controlled trial, patients initiating oxaliplatin-, carboplatin-, or irinotecan-based chemotherapy were randomized 1:1 to receive OLN or placebo on Days 1–4, with ondansetron and dexamethasone. Randomization was stratified by chemotherapy type and high-risk factors (female aged < 50 years). The primary endpoint was total protection (mild/no nausea, no vomiting, and no rescue therapy) within 120 h post-chemotherapy. Secondary endpoints included total control, complete response, nausea/vomiting severity, rescue use, adverse events, and patient satisfaction.

Results

Among 139 evaluable patients, 69 received OLN and 70 received a placebo. Total protection was achieved in 71.0% of OLN patients versus 55.7% with placebo ( p = 0.06). Total control was significantly higher with OLN (62.3% vs. 38.6%, p = 0.005). Delayed nausea (grade ≥ 2) occurred less frequently with OLN (13.0% vs. 30.0%, p = 0.015). Complete response and rescue use did not differ between groups. Somnolence rates were similar, but anorexia was less familiar with OLN. Notably, 95.6% of OLN patients preferred to continue the same regimen, compared with 72.9% of placebo recipients ( p = 0.001).

Conclusion

Olanzapine (5 mg) combined with ondansetron and dexamethasone was associated with a moderate improvement in total protection and significant improvements in no-nausea and total control rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiemeticsNauseaVomitingAntineoplastic Combined Chemotherapy ProtocolsBenzodiazepinesHumansFemaleDouble-Blind MethodDexamethasoneOlanzapineMiddle AgedOndansetronAdultMaleCarboplatinOxaliplatinDrug Therapy, CombinationIrinotecanOrganoplatinum CompoundsAgedNeoplasms

Stichwörter der Autor:innen

CarboplatinIrinotecanModerately emetogenic chemotherapyOlanzapineOxaliplatin

Substanzen

AntiemeticsDexamethasoneOlanzapineOndansetronCarboplatinOxaliplatinIrinotecanOrganoplatinum CompoundsBenzodiazepines

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Pharmacy Department, Siriraj Hospital, Bangkok, Thailand.
  • Division of Ambulatory Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. aesi105@yahoo.co.th.

Förderung

  • Siriraj Research Development Fund (Managed by Routine to Research: R2R), Mahidol University
  • Mahidol University

Zitieren

APA

Harikul, W., Nimmannit, A., Laocharoenkeat, A., Phisalprapa, P., Kositamongkol, C., Thongkijpreecha, P., & Ithimakin, S. (2026). A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy. Supportive Care in Cancer, 34(3). https://doi.org/10.1007/s00520-026-10490-8

Vancouver

Harikul W, Nimmannit A, Laocharoenkeat A, Phisalprapa P, Kositamongkol C, Thongkijpreecha P, et al. A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy. Supportive Care in Cancer. 2026;34(3). doi:10.1007/s00520-026-10490-8

BibTeX
@article{Harikul2026,
  author = {Harikul, Warangkana and Nimmannit, Akarin and Laocharoenkeat, Apirom and Phisalprapa, Pochamana and Kositamongkol, Chayanis and Thongkijpreecha, Phurita and Ithimakin, Suthinee},
  title = {A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {3},
  doi = {10.1007/s00520-026-10490-8}
}
Kostenlos starten →